| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99211 |
|
144,914 |
105,858 |
$71.15M |
| 99212 |
|
121,348 |
86,175 |
$49.66M |
| 99213 |
|
74,360 |
57,201 |
$39.24M |
| Q3014 |
Telehealth originating site facility fee |
10,535 |
8,245 |
$5.47M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
22,432 |
17,059 |
$4.96M |
| 87635 |
|
6,939 |
6,345 |
$3.57M |
| 0002A |
|
4,246 |
4,211 |
$2.13M |
| 0001A |
|
4,093 |
4,061 |
$2.01M |
| 0124A |
|
2,839 |
2,803 |
$1.52M |
| 90480 |
|
2,639 |
2,602 |
$1.46M |
| 0064A |
|
2,668 |
2,632 |
$1.37M |
| 0012A |
|
2,087 |
2,065 |
$1.01M |
| 0011A |
|
2,060 |
2,044 |
$1.00M |
| 0054A |
|
1,728 |
1,706 |
$921K |
| 0004A |
|
1,753 |
1,712 |
$893K |
| 0071A |
|
1,410 |
1,391 |
$741K |
| 0134A |
|
1,382 |
1,365 |
$699K |
| 0072A |
|
1,174 |
1,153 |
$643K |
| 0003A |
|
1,170 |
1,126 |
$546K |
| 99214 |
|
3,753 |
3,503 |
$163K |
| 0052A |
|
211 |
210 |
$127K |
| 0154A |
|
196 |
196 |
$124K |
| 90471 |
|
502 |
443 |
$111K |
| 0031A |
|
224 |
221 |
$109K |
| 51900 |
|
266 |
246 |
$109K |
| 0074A |
|
171 |
171 |
$108K |
| 0051A |
|
158 |
154 |
$88K |
| 0081A |
|
119 |
119 |
$76K |
| 91320 |
|
114 |
114 |
$73K |
| 0111A |
|
98 |
97 |
$62K |
| 99308 |
|
1,940 |
1,931 |
$53K |
| 97110 |
|
1,769 |
915 |
$42K |
| 91322 |
|
62 |
62 |
$39K |
| 0082A |
|
59 |
59 |
$38K |
| 0112A |
|
48 |
48 |
$31K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
91 |
87 |
$20K |
| 91301 |
|
101 |
99 |
$20K |
| 92014 |
|
450 |
444 |
$19K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
34 |
33 |
$14K |
| 99282 |
|
160 |
160 |
$12K |
| 91319 |
|
19 |
19 |
$12K |
| 90686 |
|
1,109 |
1,093 |
$10K |
| G0008 |
Administration of influenza virus vaccine |
2,475 |
2,448 |
$9K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
27 |
26 |
$9K |
| 0034A |
|
17 |
17 |
$9K |
| 0164A |
|
12 |
12 |
$8K |
| 90674 |
|
125 |
124 |
$7K |
| 99309 |
|
161 |
155 |
$6K |
| 71045 |
|
1,317 |
1,152 |
$6K |
| 99281 |
|
28 |
26 |
$6K |
| 99283 |
|
79 |
77 |
$5K |
| 74177 |
|
195 |
192 |
$5K |
| 99305 |
|
74 |
74 |
$5K |
| 43239 |
|
30 |
29 |
$5K |
| 99232 |
|
96 |
40 |
$5K |
| 71046 |
|
900 |
871 |
$4K |
| 92340 |
|
92 |
92 |
$4K |
| 45378 |
|
25 |
25 |
$4K |
| 90746 |
|
354 |
353 |
$3K |
| D0220 |
|
75 |
41 |
$2K |
| 99223 |
Prolong inpt eval add15 m |
14 |
12 |
$2K |
| 99306 |
Prolong nursin fac eval 15m |
44 |
41 |
$2K |
| 90677 |
|
275 |
275 |
$1K |
| 99233 |
Prolong inpt eval add15 m |
16 |
12 |
$1K |
| 90662 |
|
300 |
300 |
$1K |
| Q2038 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) |
791 |
780 |
$1K |
| G0010 |
Administration of hepatitis b vaccine |
352 |
351 |
$964.08 |
| 99239 |
|
12 |
12 |
$948.12 |
| 99215 |
Prolong outpt/office vis |
64 |
63 |
$853.55 |
| 99284 |
|
24 |
24 |
$769.46 |
| 97161 |
|
38 |
37 |
$656.49 |
| G0009 |
Administration of pneumococcal vaccine |
427 |
426 |
$586.34 |
| 90670 |
|
27 |
27 |
$557.50 |
| 70450 |
|
56 |
55 |
$556.19 |
| 85025 |
|
86 |
78 |
$519.00 |
| 99204 |
|
28 |
28 |
$428.49 |
| 90694 |
|
354 |
352 |
$412.05 |
| 90688 |
|
79 |
77 |
$403.05 |
| 92012 |
|
28 |
25 |
$107.79 |
| 11721 |
|
13 |
13 |
$78.15 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
61 |
57 |
$58.13 |
| 73030 |
|
13 |
13 |
$21.48 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
92 |
84 |
$0.00 |
| 90656 |
|
12 |
12 |
$0.00 |